{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CC-220+2+mg", "query": { "intervention": "CC-220 2 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CC-220+2+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T12:02:51.798Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03310619", "title": "A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Follicular" ], "interventions": [ { "name": "JCAR017", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "CC-122", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "CC-220", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "CC-99282", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2017-12-20", "completion_date": "2023-02-15", "has_results": true, "last_update_posted_date": "2024-04-04", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 9, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310619" }, { "nct_id": "NCT04975997", "title": "Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 939, "start_date": "2022-06-23", "completion_date": "2032-06-25", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 43, "location_summary": "Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975997" }, { "nct_id": "NCT05434689", "title": "COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Iberdomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 80, "start_date": "2023-01-18", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05434689" }, { "nct_id": "NCT05199311", "title": "Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Oral Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2022-05-13", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199311" }, { "nct_id": "NCT03135509", "title": "A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "CC-220", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2017-05-24", "completion_date": "2017-06-28", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03135509" }, { "nct_id": "NCT06518551", "title": "Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloma", "Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Omar Nadeem, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2024-11-01", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06518551" }, { "nct_id": "NCT02773030", "title": "A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CC-220", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab - 16mg/kg", "type": "DRUG" }, { "name": "Bortezomib (BTZ)", "type": "DRUG" }, { "name": "Daratumumab- 1800mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 466, "start_date": "2016-10-14", "completion_date": "2028-07-28", "has_results": true, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 58, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02773030" }, { "nct_id": "NCT02185040", "title": "A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "CC-220", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2014-09-16", "completion_date": "2018-09-25", "has_results": true, "last_update_posted_date": "2020-03-19", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02185040" }, { "nct_id": "NCT02820935", "title": "Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "CC-220", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2016-07", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-10-18", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02820935" }, { "nct_id": "NCT04464798", "title": "A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "CC-220", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2020-11-11", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-04T12:02:51.798Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04464798" } ] }